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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is often associated with recurrent hospitalizations. This
study aimed to identify factors related to COPD rehospitalization.
Methods: A national US claims database was used to identify patients, aged ≥40 years, hospitalized for COPD. Their
first COPD-related hospital admission date in 2009 was set as the index date, with post-discharge COPD-related
rehospitalization assessed for 180 days post-index date. Data were analyzed for: 1) all eligible patients in whom
early COPD-related rehospitalization was evaluated (1–30 days post discharge; all-patient cohort) and 2) a patient
subset not rehospitalized early in whom late COPD-related rehospitalization was evaluated (>30 days post discharge to
180 days post-index date; late cohort). Logistic regressions controlling for age and sex assessed potential COPD-
related rehospitalization predictors. Variables from the 360-day pre-index period and index hospitalization were
evaluated for each cohort, and 30-day post-discharge variables evaluated for the late cohort.
Results: Of 3612 patients with an index hospitalization, 4.8 % (174) had an early COPD-related rehospitalization, and of
the remaining 3438 patients, 13.7 % (471) had a late COPD-related rehospitalization. Several pre-index variables were
predictive of early COPD-related rehospitalization including: pneumonia; comorbidities; COPD-related drug therapies; and
prior hospitalizations. In patients not rehospitalized early, the strongest predictor of late COPD-related rehospitalization
was pre-index COPD-related hospitalization (OR = 3.64 [P < 0.001]). The strongest index hospitalization factors predictive
of late COPD-related rehospitalization were use of steroids (any route: OR = 1.62 [P = 0.007]) and nebulizers
(OR = 1.65 [P = 0.007]); neither predicted early COPD-related rehospitalization. Generally, factors predicting
COPD-related rehospitalization were similar in both cohorts.
Conclusions: Several pre-index variables were associated with COPD-related rehospitalization. A strong predictor of
COPD-related rehospitalization was prior hospitalization during the pre-index period, particularly with a primary COPD
diagnosis, whilst other predictive factors related to increased COPD severity; these may be useful indicators for COPD-
related rehospitalization risk assessment. Some factors, e.g., recurrent pneumonia and exacerbations, may be modifiable.
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by persistent airflow limitation and is associ-
ated with an enhanced chronic inflammatory response
in the lungs to noxious particles or gases [1]. Although
the primary effect of COPD is on the lungs, it is also as-
sociated with the development of adverse systemic ef-
fects and comorbidities, which contribute to its severity
[2–4]. COPD is a major cause of chronic morbidity and
mortality [1]; worldwide in 2010, it affected more than
210 million individuals [5] and was one of the top six
leading causes of death [6]. In 2015, the World Health
Organization estimated that approximately 65 million
individuals had moderate-to-severe COPD and projected
it to become the third leading cause of death globally by
2030 [7]. In 2012, chronic lower respiratory diseases, in-
cluding COPD, were the third leading cause of deaths in
the United States [8] and, in 2013, an estimated 15.7
million adults had physician-diagnosed COPD [9]. In
2012, the National Heart, Lung, and Blood Institute
(NHLBI) estimated that around 12 million individuals in
the United States had undiagnosed COPD [10].
Patients with COPD often experience acute worsening
of respiratory symptoms, known as exacerbations, which
range in severity from mild events that patients man-
age themselves at home to severe episodes that require
hospitalization. Recurrent COPD exacerbations, par-
ticularly those requiring hospitalization, have been
shown to hasten lung function decline and increase pa-
tient mortality, as well as have a deleterious impact on
health-related quality of life [11–13]. According to the
American Thoracic Society/European Respiratory Society
task force [14], indications for hospitalization of patients
with an exacerbation include: occurrence of high-risk
comorbidities (e.g., pneumonia, cardiac arrhythmia,
congestive heart failure, diabetes mellitus, renal or liver
failure); inadequate response of symptoms to outpatient
management; marked increase in dyspnea; inability to
eat or sleep because of symptoms; worsening hypoxemia
or hypercapnia; alterations in mental status; inability of
patients to care for themselves (lack of home support); un-
certain diagnosis; and inadequate home care.
COPD-related hospitalizations place a substantial eco-
nomic burden on healthcare systems, and account for a
large portion of the direct medical costs that are covered
from a payer perspective [10]. In the United States, med-
ical costs attributable to COPD were estimated at US
$32.1 billion in 2010, and with current growth are pre-
dicted to rise to US $49.0 billion by 2020 [15]. COPD is
also one of the major causes of early rehospitalization;
approximately one in every five Medicare patients hospi-
talized for COPD have an all-cause rehospitalization
within 30 days of discharge and around a third of these
patients are readmitted for a COPD-related event [16].
Healthcare policy makers have identified reducing hospital
readmissions as a way of improving healthcare quality
while reducing costs, and in the United States the main
public health insurance system has implemented a policy
wherein hospitals will be penalized for rehospitalizations
within 30 days after hospitalization for COPD [17]. This
policy has been implemented despite a lack of specific
interventions proven to reduce COPD-related rehospi-
talization [18]. Hospitals are now keenly interested in
identifying patients with COPD who are at highest risk
for hospital readmission, and in finding interventions
that reduce rehospitalization risk.
The purpose of this study was to identify factors asso-
ciated with COPD-related rehospitalization post dis-
charge from an index hospitalization for COPD using
variables that are typically available in administrative
claims or encounter databases. We were particularly in-
terested in the following characteristics: 1) demographic
factors; 2) comorbid conditions in the pre-index period
(360 days prior to the index admission); 3) use of COPD-
related drugs in the pre-index period; 4) COPD-related
and all-cause healthcare utilization in the pre-index period;
5) treatments during the index hospitalization; and 6) office
visits and antibiotic or oral steroid treatments in the month
after the index hospitalization. We stratified the post-index
hospitalization period into two time periods: early (within
1–30 days post discharge) and late (>30 days post dis-
charge to the end of the post-index period [i.e., 180 days
from the index admission]), which allows examination of
factors most relevant to those dealing with recent man-
dates while also allowing comparison with previous
analyses. We chose to focus solely on COPD-related
rehospitalizations, rather than all-cause rehospitaliza-




Data for this analysis were from SDI Health, which was
acquired by IMS Health in 2011. The sources of SDI
data are from national US claims clearinghouses and fa-
cilities including both hospital inpatient and outpatient
details. According to SDI, at the time of data extraction
there were nearly 20 million discharges captured annu-
ally with 4.5 million of these also capturing physician
office-based encounters and nearly 4 million with office
and prescription coverage (personal communication). All
available hospital, office visit, and outpatient pharmacy
claims were obtained for patients meeting the analysis
criteria.
The retrospective SDI patient claims data were de-
identified to ensure compliance with the Health Insur-
ance Portability and Accountability Act (HIPAA) Privacy
Rule standard for de-identification. Therefore, neither
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institutional review board approval nor informed patient
consent were required for this study.
Observation periods
The initial data extraction selected patients with any
COPD-related diagnosis in 2008 through 2011. The time
period of January 1, 2009 through December 31, 2009
was used to identify patients who had an inpatient
hospitalization for COPD (i.e., the index event). The date
of hospital admission was set as the index date and the
post-index period was the first 180 days from the index
admission. The SDI data did not include any informa-
tion regarding health insurance coverage eligibility,
which is frequently used in administrative database ana-
lyses to ensure completeness of the data. Therefore,
proxy eligibility was required, which was established by
claim activity (one pharmacy and one medical) for any
reason between −720 and −361 days relative to the
index date (i.e., pre-period eligibility indicator) and be-
tween +181 to +720 days relative to the index date (i.e.,
post-period eligibility indicator).
Two time periods for evaluating COPD-related re-
hospitalization were based on the discharge date from
the index hospitalization; 1–30 days post discharge
and >30 days post discharge to the end of the post-
index period. A 360-day pre-index period and the
index hospital event were used for identifying pre-
index and in-hospital predictors. The first 30 days fol-
lowing discharge from the index hospitalization was
also used for identifying predictors for patients whose
first COPD-related rehospitalization occurred later in
the observation period. A diagram showing the ana-
lysis observation periods is presented in Fig. 1.
Analysis population
Patients were included in the study if they had a COPD-
related hospitalization within the enrolment window
(index event), were aged ≥40 years at the time of the
index event, and met the proxy eligibility requirement. It
was assumed that patients who met the proxy eligibility
criterion had complete medical, pharmacy, and hospital
data for the analysis period (−360 days before and 180 days
after index hospitalization). COPD-related hospitalization
was defined based on International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM)
codes (491.xx–Chronic bronchitis; 492.xx–Emphysema;
493.2x–Chronic obstructive asthma, or 496-Chronic air-
way obstruction, not elsewhere classified).
Patients were excluded if they had: incomplete or in-
valid data for variables used in the analysis; a docu-
mented diagnosis of pregnancy, malignant neoplasm, or
cystic fibrosis; hospice claims; an indication of multiple
hospitalizations on the index date; index hospitalization
costs ≥ $270,000; or lung transplant claims prior to the
index date. The goal of the exclusion criteria was to re-
move patients who had non-COPD conditions that
would influence hospitalizations ultimately affecting the
rehospitalization rate.
Primary endpoint
The primary endpoint for the study was the first COPD-
related rehospitalization post discharge from the index
event. In order to place this endpoint in context, the
percentages of patients rehospitalized for any reason
within 30 days of discharge and within 180 days of dis-
charge were also calculated.
Data analysis
Analysis groups
Analyses were conducted on two data sets. The first data
set, referred to as the ‘all-patient cohort’, consisted of all
eligible study patients, and was used to investigate the
predictors of early COPD-related rehospitalization (i.e.,
within 1–30 days post discharge). The second data set,
referred to as the ‘late cohort’, consisted of all eligible
study patients except those who had their first COPD-
Fig. 1 Study timeline and design
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related rehospitalization within 30 days post discharge.
This second data set was used to investigate the predictors
of late COPD-related rehospitalization (i.e., from >30 days
post discharge to the end of the post-index period).
Coding
Operational definitions were developed for study vari-
ables from the 360-day pre-index period and for the in-
hospital data. The in-hospital data consisted of Charge
Description Master entries, which detail items billed to
patients in an inpatient setting. Charge Description Master
entries were qualitatively reviewed, and entries potentially
related to COPD were coded. For the in-hospital data, the
following types of variables were coded indicating pres-
ence or use: comorbidities; vaccines; smoking or history of
smoking; transplantation; oxygen use; antibiotics; inhaled
and oral steroids; xanthines; and oral and inhaled bron-
chodilators. For healthcare utilization other than inpatient,
study variables were assessed using codes for ICD-9-CM,
Current Procedural Terminology (CPT), Healthcare
Common Procedure Coding System (HCPCS), and drug
categories based on National Drug Codes (NDC). These
variables included patients’ demographic data, comorbidi-
ties determined either by diagnosis or prescriptions, pre-
index medications (long-acting beta-agonists [LABAs],
short-acting beta-agonists [SABAs], steroids, COPD-related
therapies), resource utilization, and variables from the first
30 days post discharge from the index hospitalization. A list
of all variables used in the analyses is available in Additional
file 1: Table S1.
Statistical analysis
Categorical variables were summarized using frequencies
and percentages, and continuous measures using mean ±
standard deviation (SD). Each predictor was run in a logis-
tic regression model controlling for sex and age (with the
exception that age was controlled for sex, and sex con-
trolled for age). Since the nature of this study was explora-
tory, no adjustments for multiplicity were applied. Odds
ratios (OR) and 95 % confidence intervals (CI) for the
predictors, indicating their relative association with the
likelihood of having an early or a late COPD-related rehos-
pitalization post discharge from the index hospitalization
were calculated. All data were analyzed using SAS® Version
9.2 software (SAS Institute, Cary, NC, USA).
Results
Sample attrition and analysis group assignment
The sample attrition data are shown in Fig. 2. The initial
data extraction process selected 356,554 patients with a
diagnosis of interest in any field during 2008–2011. This
number was reduced to 36,378 when only patients
Fig. 2 Sample attrition. ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification
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having a hospitalization with a primary diagnosis of inter-
est during the 2009 enrollment window were selected.
The proxy eligibility requirement excluded 31,049 patients
and a further 1717 patients were omitted as a result of the
exclusion criteria.
There were 3612 patients meeting all inclusion and no
exclusion criteria. From post discharge to the end of the
180-day post-index period, 17.9 % (645/3612) of these pa-
tients had a COPD-related rehospitalization and 39.2 %
(1417/3612) had an all-cause hospitalization. For the all-
patient cohort, 4.8 % (174/3612) of patients had a first
COPD-related rehospitalization within 30 days post dis-
charge from the index hospitalization. Of the remaining
3438 patients (i.e., the late cohort), 13.7 % (471/3438)
had a first COPD-related rehospitalization that occurred
>30 days post discharge. In the all-patient cohort, patients
with a first COPD-related rehospitalization during the first
30 days post discharge represented 36.2 % (174/481) of all
patients experiencing at least one all-cause rehospitaliza-
tion during this period. From >30 days post discharge to
the end of the 180-day index period, the proportion of pa-
tients with a first COPD-related rehospitalization versus
all-cause rehospitalization was 50.3 % (471/936 patients).
Pre-index event variables
Demographic characteristics
Descriptions of the demographic characteristics for the
all-patient and late cohorts are provided in Table 1. In-
dependent logistic regression results indicated that in
the all-patient cohort, younger age (OR = 0.98 for each year
older [P = 0.007]) and Medicare insurance status (OR = 1.40
[P = 0.042]) were predictive of early COPD-related rehospi-
talization (i.e., occurring within 30 days post discharge from
the index hospitalization). Whereas, male sex (OR = 1.34
[P = 0.005]), claims for smoking cessation products in the
pre-index period (OR = 1.51 [P = 0.008]) and a pre-index
indication of tobacco/smoking issues (i.e., diagnosis
[history/use disorder], or HCPCS or CPT codes for
past or present smoking or smoking cessation; OR =
1.74 [P < 0.001]) had greater odds of a COPD-related
rehospitalization ≥30 days post discharge from the
index hospitalization.
Comorbidities
Pre-index comorbidities, assigned based on diagnosis,
and the adjusted ORs for COPD-related rehospitaliza-
tions are provided in Fig. 3. Anxiety, asthma, diabetes,
Table 1 Demographic characteristics of patients with COPD in the all-patient and late cohortsa
Characteristic All-patient cohort (n = 3612) Late cohort (n = 3438)
Early COPD-related rehospitalization Late COPD-related rehospitalization
Yes (n = 174) No (n = 3438) P-valueb Yes (n = 471) No (n = 2967) P-valueb
Age, years 64.2 ± 11.7 66.7 ± 12.1 0.007 66.3 ± 11.5 66.7 ± 12.2 0.513
Age group
40–49 years 21 (12.1) 338 (9.8) 0.336 39 (8.3) 299 (10.1) 0.224
50–59 years 46 (26.4) 705 (20.5) 0.060 111 (23.6) 594 (20.0) 0.077
60–69 years 49 (28.2) 861 (25.0) 0.355 120 (25.5) 741 (25.0) 0.815
70–79 years 34 (19.5) 897 (26.1) 0.054 127 (27.0) 770 (26.0) 0.642
≥80 years 24 (13.8) 637 (18.5) 0.115 74 (15.7) 563 (19.0) 0.090
Male 64 (36.8) 1121 (32.6) 0.252 180 (38.2) 941 (31.7) 0.005
Medicare 97 (55.7) 1756 (51.1) 0.229 237 (50.3) 1519 (51.2) 0.723
Any indication of tobacco/smoking
issues pre-index
70 (40.2) 1113 (32.4) 0.031 204 (43.3) 909 (30.6) <0.001
Smoking cessation products pre-index 24 (13.8) 326 (9.5) 0.061 61 (13.0) 265 (8.9) 0.006
Regionc
North 30 (17.2) 511 (14.9) 0.391 81 (17.2) 430 (14.5) 0.125
South 73 (42.0) 1439 (41.9) 0.980 176 (37.4) 1263 (42.6) 0.034
East 39 (22.4) 743 (21.6) 0.802 113 (24.0) 630 (21.2) 0.177
West 27 (15.5) 594 (17.3) 0.548 81 (17.2) 513 (17.3) 0.961
Unknown region 5 (2.9) 151 (4.4) 0.336 20 (4.2) 131 (4.4) 0.868
Data are number of patients (%) or mean ± SD
aThe all-patient cohort consisted of all patients in whom COPD-related rehospitalization was evaluated 1–30 days post discharge and the late cohort consisted of
the subset of patients not rehospitalized early in whom late COPD-related rehospitalization was evaluated (>30 days post discharge to 180 days
post-index hospitalization)
bP-values are from chi-square tests for unadjusted percentages and independent t tests for unadjusted means
cRegion is based on the region where the hospital is located
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Fig. 3 (See legend on next page.)
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dyspnea, hypoxia, ischemic heart disease, and a pneumo-
nia code anytime during the 360-day pre-index period
were predictors of early and late COPD-related rehospi-
talizations. In addition to these parameters, congestive
heart failure, depression, hypertension, osteoporosis, and
pulmonary vascular disease were also predictive of late
COPD-related rehospitalization. The strongest predictor
of late COPD-related rehospitalization was pneumonia
within 90 days prior to the index hospitalization (OR =
2.11 [P < 0.001]). The OR estimates for early COPD-
related rehospitalization were similar to those for late
COPD-related rehospitalization, but fewer comorbidities
achieved statistical significance. The Charlson comorbidity
score was not significantly predictive of either an early or
late COPD-related rehospitalization.
Data for treated comorbidities, assigned based on thera-
peutic categories of prescriptions dispensed during the
360-day pre-index period were explored. The categories
that were predictive of an early COPD-related rehospitali-
zation were greater use of blood products (i.e., blood de-
rivatives and blood forming/coagulation agents; OR = 1.55
[P = 0.031]), cardiovascular drugs (i.e., blood pressure and
cholesterol-lowering agents; OR = 1.41 [P = 0.038]) and
hormones (i.e., steroids, estrogens, testosterones; OR =
1.55 [P = 0.008]). Presence of claims for antiarrhythmics
was associated with a lower risk of a late rehospitalization
(OR = 0.77 [P = 0.027]) and presence of claims for anti-
asthmatics (OR = 1.77 [P < 0.001]), gastrointestinal
drugs (OR = 1.23 [P = 0.039]) and hormones (OR = 1.71
[P < 0.001]) were associated with a greater risk of late
rehospitalization. A greater number of different drug
classes per patient, including COPD classes (OR = 1.04
[P = 0.015]) was also predictive of a late COPD-related
rehospitalization.
Respiratory-related therapies
Pre-index outpatient respiratory-related prescription
drug therapies (one or more fills) with adjusted ORs
for COPD-related rehospitalization are provided in
Fig. 4. For the drug variables, data are only presented
for those generic entities for which ≥5 % of patients
had claims.
Pre-index prescription (NDC billed) or office-based
(HCPCS billed) antibiotics within 3 days of a COPD diag-
nosis were predictive of both early and late COPD-related
rehospitalization (OR = 1.65 [P = 0.001] and OR = 2.19
[P < 0.001], respectively). The mean number of times
that an antibiotic was prescribed within 3 days of a
COPD diagnosis, suggestive of a moderate COPD ex-
acerbation, was also predictive of an early and late
COPD-related rehospitalization (OR = 1.22 [P = 0.002]
and OR = 1.20 [P < 0.001], respectively).
Odds for an early COPD-related rehospitalization were
higher for patients with pre-index availability of at least
one SABA or LABA (OR = 1.60 [P = 0.021]) and non-
inhaled steroids (OR = 1.68 [P = 0.001]). Pre-index
inhaled steroid use was not predictive of early COPD-
related rehospitalization. Patients had greater odds of a
late COPD-related rehospitalization if they had claims in
the pre-index period for at least one SABA or LABA
(OR = 2.68), inhaled steroids (OR = 1.72), or non-inhaled
steroids (OR = 1.75); all were statistically significant at
P < 0.001. Data stratified by quarters prior to the
index hospitalization were also examined, but did not
reveal additional information.
Overall, presence of respiratory-related therapies was
more predictive of a late than early COPD-related rehos-
pitalization. The absolute differences for those with and
without an early COPD-related rehospitalization were
<10 % for all medications except prednisone, and were
<10 % for all medications except albuterol, fluticasone,
prednisone, and tiotropium in those with and without a
late COPD-related rehospitalization. The adjusted ORs
of COPD-related rehospitalization for oral prednisone
use were 1.70 (P < 0.001) and 1.80 (P < 0.001) for early
and late rehospitalizations, respectively; and were only
slightly greater than those for inhaled medications.
A greater documentation of influenza vaccination
was predictive of early COPD-related rehospitalization
(OR = 1.50 [P = 0.015]), but not late COPD-related
rehospitalization.
Healthcare utilization
Pre-index hospitalization resource use with adjusted
ORs for COPD-related rehospitalization are provided in
Fig. 5.
All-cause hospitalization in the pre-index period was
strongly predictive of both early and late COPD-related
rehospitalization (OR = 1.67 [P < 0.001] and OR = 2.10
[P < 0.001], respectively). A pre-index hospitalization
with a primary diagnosis for COPD was shown to be an
even stronger predictor of early and late COPD-related
rehospitalization (OR = 2.20 [P = 0.002] and OR = 3.64
[P < 0.001], respectively).
(See figure on previous page.)
Fig. 3 Diagnosis-based comorbidities identified in the 360-day pre-index period. Adjusted odds of (a) early and (b) late COPD-related rehospitalizations.
The early cohort consisted of all patients in whom COPD-related rehospitalization was evaluated 1–30 days post discharge and the late cohort consisted of
the subset of patients not rehospitalized early in whom late COPD-related rehospitalization was evaluated (>30 days post discharge to 180 days post-index
hospitalization). Each factor was adjusted for sex and age in a logistic regression model. Data are number of patients (%) or mean ± SD.
CI, confidence interval
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Pre-index visits to primary care, respiratory-related and
non-respiratory-related specialist were not predictive of
either early or late COPD-related rehospitalization.
The total number of prescription claims (in units of
10) pre-index attained ORs that were statistically sig-
nificant for early COPD-related rehospitalization (OR =
1.03 [P = 0.040]) and late COPD-related rehospitaliza-
tion (OR = 1.02 [P = 0.016]).
Index hospitalization
Treatment during the index hospitalization yielded few
unexpected factors associated with COPD-related rehos-
pitalization. Only the statistically significant findings are
presented. Overall, more than 90 % of patients were
treated with steroids and bronchodilators; it is likely that
those not receiving these therapies were either misclassi-
fied, received drugs billed under bundled services, or were
drug intolerant. Factors with higher odds of a late COPD-
related rehospitalization included a higher number of
COPD-related drug categories appearing in the index
hospitalization (anticholinergics [tiotropium or ipratro-
pium] and other bronchodilators by any route [see Add-
itional file 1: Table S1 for generic drugs included] and
steroids by inhalation: OR = 1.17 [P = 0.005]), and the use
of steroids (any route: OR = 1.62 [P = 0.007], inhaled: OR
= 1.42 [P < 0.001], and oral/injectable: OR = 1.46 [P =
0.015]) or nebulizers (OR = 1.65 [P = 0.007]). Treatment
during the index hospitalization was not predictive of an
early COPD-related rehospitalization.
Interestingly, index hospitalization at teaching hospi-
tals (approximately one-third of the cohorts) was also
associated with increased risk of late COPD-related re-
hospitalization (OR = 1.25 [P = 0.027]), but not early
COPD-related rehospitalization.
Post-index variables
Among the factors examined in the 30 days post-index
hospitalization discharge, only one or more claims for
an oral steroid was significantly associated with a late
COPD-related rehospitalization (Fig. 6). Having an office
visit in the first month after hospital discharge was not as-
sociated with a COPD-related rehospitalization >30 days
post discharge (P = 0.550).
Discussion
The aim of this exploratory analysis was to identify fac-
tors associated with COPD-related rehospitalization fol-
lowing a hospitalization for COPD. This retrospective
analysis utilized a unique data source, which contained
inpatient pharmacy data as well as medical and out-
patient pharmacy claims data from the pre- and post-
index hospitalization periods. Patients who experienced
a COPD-related rehospitalization differed from those
who did not experience a COPD-related rehospitaliza-
tion on many pre-index hospitalization event variables
including: a greater proportion of patients with some
evidence of current or prior smoking; more frequent
comorbidities (e.g., anxiety, asthma, diabetes, dyspnea,
hypertension, hypoxia, ischemic heart disease, osteoporosis,
and pneumonia); a greater use of COPD-related drug ther-
apies (e.g., antibiotics, steroids, and bronchodilators); and
more frequent hospitalizations (any reason, respiratory-
related, or COPD-related). Most of these factors are likely
to be markers of greater COPD severity. Although factors
associated with late COPD-related rehospitalization were
more likely to achieve statistical significance due to the
greater length of time over which patients were observed
(i.e., allowing for a greater number of patients with a
rehospitalization), generally, among the factors that
were available in the database, similar factors were
found to be associated with early and late COPD-
related rehospitalization.
These analyses identified several clinical parameters
that might be useful for developing risk assessment sys-
tems for hospitalized COPD patients, and a few of the
parameters associated with COPD-related rehospitaliza-
tion are potentially modifiable. Pneumonia events and
the use of antibiotics in the pre-index period were
strongly associated with early and late COPD-related re-
hospitalization. A strong relationship between pneumo-
nia and COPD rehospitalizations was also noted in an
analysis of 2003–2004 Medicare claims data [16]. Regu-
lar daily use of azithromycin has been shown to reduce
the frequency of COPD exacerbations, including those
that result in hospitalization [19]. Perhaps, more attention
to patients with COPD with a history of frequent bronchitis
or pneumonia could reduce their COPD-related re-
hospitalization rates. Another potentially modifiable
parameter is the generally poor adherence to COPD
(See figure on previous page.)
Fig. 4 Outpatient prescription pharmacy utilization during the pre-index period. Adjusted odds of (a) early and (b) late COPD-related rehospitalizations.
The early cohort consisted of all patients in whom COPD-related rehospitalization was evaluated 1–30 days post discharge and the late cohort consisted of
the subset of patients not rehospitalized early in whom late COPD-related rehospitalization was evaluated (>30 days post discharge to 180 days post-index
hospitalization). Each factor was adjusted for sex and age in a logistic regression model. Use is one or more fills unless otherwise indicated. The generic
drugs include only non-injectable National Drug Code (NDC)-based drug claims appearing in the pharmacy database. All claims are collapsed by generic
name, regardless of administration route. Only drugs used by ≥5 % of patients are reported. aAntibiotics were only counted where they occur on or within
3 days following a respiratory-related diagnosis. Data are number of patients (%) or mean ± SD. CI, confidence interval
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controller medications in the pre-index period. The ob-
served association between respiratory medication use
and an increased risk of COPD-related rehospitalization,
most likely represents a bias by indication, wherein use of
the medication is a marker for patients with more severe
COPD. We found that adherence to COPD medications
Fig. 5 Pre-index period hospitalizations, outpatient clinic visits, and outpatient pharmacy claims. Adjusted odds of (a) early and (b) late COPD-related
rehospitalization. The early cohort consisted of all patients in whom COPD-related rehospitalization was evaluated 1–30 days post discharge and the
late cohort consisted of the subset of patients not rehospitalized early in whom late COPD-related rehospitalization was evaluated (>30 days post
discharge to 180 days post-index hospitalization). Each factor was adjusted for sex and age in a logistic regression model. Data are number of patients
(%) or mean ± SD. CI, confidence interval
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was poor even among those with early and late COPD-
related rehospitalizations, with an average of only 38.5 and
45.2 %, respectively, of their pre-index period days covered
by any respiratory medication. COPD controller medica-
tions have proven efficacy in reducing COPD exacerba-
tions, and it is possible that better COPD treatment in this
population could reduce both index hospitalizations and
COPD-related rehospitalizations.
In our database, all-cause rehospitalization within 1–
30 days post discharge and within 1 day post discharge
to the end of the 180-day post-index period (13.3 %
[481/3612 patients] and 39.2 % [1417/3612 patients], re-
spectively) and COPD-related rehospitalization (4.8 %
[174/3612 patients] and 17.9 % [645/3612 patients], re-
spectively) were similar to, or lower than, those reported
in other recent analyses. Our estimates may be lower, in
part, since patients who died within 180 days of the
index hospitalization were not included in our analysis.
In an analysis of the 2003–2004 US Medicare popula-
tion, the 30-day rehospitalization rates after a COPD ad-
mission were 22.6 % for all causes and 8.2 % primarily
for COPD [16]. In a limited analysis of 2008 fee-for-
service data, the 30-day rehospitalization rates after a
COPD admission were 20.5 % for all causes and 7.1 %
primarily for COPD [20]. In an analysis of another US
insurance claims database of patients aged 40–65 years
who were hospitalized for COPD between 2008 and
2010, the 30-day rehospitalization rates after a COPD
admission were 8.2 % for all causes and 5.6 % primarily
for COPD [21]. As in our study, this study also identified
pre-index hospitalization healthcare utilization and co-
morbidity factors that were associated with an increased
risk of all- cause and COPD-related rehospitalizations,
even though their pre-index period was limited to
90 days [21]. In a sample of COPD admissions in the
United Kingdom in 2008, the 90-day all-cause readmis-
sion rate was 34.2 % (2971/8677 patients) [22]. In a
study of hospital readmissions for chronic medical con-
ditions in Denmark and in the US Kaiser Permanente
system from 2002 to 2007, all-cause 30-day readmission
rates after a COPD hospitalization ranged from 20.7 to
24.1 % in Denmark, and from 19.4 to 21.4 % in Kaiser
Permanente [23]. Another study of US claims data, using
an analysis approach similar to ours, also found that
factors associated with COPD severity at baseline (e.g.,
oxygen therapy, respiratory medicine use, and pulmonol-
ogist visits) were predictors of COPD-related readmis-
sion within 30 days [24].
In our analysis, having a prior hospitalization for
COPD and the number of respiratory-related hospitali-
zations were strongly associated with greater odds of a
rehospitalization. While we were not able to assess each
patient’s total exacerbation experience, the finding does
support the concept that there is a subset of patients
who could be classified as “frequent exacerbators”; a
classification that has been previously defined to include
patients not only with severe airflow limitation, but also
patients with moderate airflow limitation [25–27].
This study has some limitations. Administrative data
were based on claim payments and not clinical treat-
ment. We included as broad a range of variables as pos-
sible, based on what was available in the administrative
database, but we recognize that there were many vari-
ables not captured by the database that might more ac-
curately predict COPD-related rehospitalization. These
include knowledge about the severity of each patient’s
Fig. 6 Office visits and medication claims in the 30 days post discharge from the index hospitalization. Adjusted odds of late COPD-related
rehospitalization in the subset of patients not rehospitalized early in whom late COPD-related rehospitalization was evaluated (>30 days post
discharge to 180 days post-index hospitalization). Each factor was adjusted for sex and age in a logistic regression model. aAntibiotics
were only counted where they occur on or within 3 days following a respiratory-related diagnosis. Data are number of patients (%). CI,
confidence interval
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obstructive lung disease prior to and during the index
hospitalization, assessment of partial pressure of carbon
dioxide in arterial blood (PCO2), and the use of invasive
and noninvasive ventilation. Additionally, inpatient stay
information may not have completely captured hospi-
talization treatments; for example, patients may have
had existing therapy on hand from prior to the index
hospitalization. The extent to which coding within hos-
pitals’ Charge Description Masters accurately reflect the
care that a patient receives is unknown and it is possible
that patients received care that was billed using termin-
ology where it was not possible to associate the charge
description with the correct category. Another limitation
is that patients who died within 180 days of the index
hospitalization were excluded from the analysis. This
may create a bias that has an unknown effect. In this
study we only focused on COPD-related rehospitaliza-
tion and not on all-cause rehospitalization; some of the
predictors of COPD-related rehospitalization may not be
applicable to all-cause rehospitalization.
A large number of tests were performed and no cor-
rection was made for multiplicity. It is likely that some
of the statistically significant tests were spurious. Since
this analysis was exploratory, we elected to be more inclu-
sive in order not to miss potential predictors. P-values and
CIs are provided to allow readers to evaluate the level of
significance. No multivariable models were assessed. No
commentary is possible on the causal pathways or interre-
lationships among the variables.
A further limitation is that the analysis focused on a
narrow definition of relapse, i.e., only COPD-related
rehospitalizations were included; it is recognized that
using rehospitalization as a marker for relapse underre-
presents the total number of COPD relapses that occur,
because patients not requiring rehospitalization were ex-
cluded. However, it does signify an important endpoint
from an economic and humanistic perspective. It is also
noteworthy that there is no definitive approach for iden-
tifying COPD-related hospitalizations. In the broadest
sense, all hospitalizations may be affected by COPD.
Conclusions
In this study, patients who experienced a COPD-related
rehospitalization were significantly different from those
who did not, on several pre-index hospitalization factors
(smoking, comorbidities, COPD-related therapies, and
more frequent hospitalizations, as well as more severe
COPD). A strong predictor of a COPD-related rehospitali-
zation was prior hospitalization, particularly with a primary
COPD diagnosis. In-hospital and post-hospitalization vari-
ables had minimal effect on COPD-related rehospitalization
risk as assessed in this study. Prospective analyses can focus
on the parameters that were most strongly associated
with COPD-related rehospitalization for the purposes
of developing risk stratification systems, and for devel-
oping specific interventions that might reduce COPD-
related rehospitalizations.
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